Table 3.
Example of fold change calculation and change in rank probabilities for Cooper 200618 network
| Treatment | Full model | Reduced model | Fold change* | |||
|---|---|---|---|---|---|---|
| Relative rate v placebo (95% CI) | Probability (%) | Relative rate v placebo (95% CI) | Probability (%) | |||
| Warfarin: | ||||||
| Adjusted standard dose | 0.37 (0.26 to 0.53) | 3 | 0.41 (0.27 to 0.7) | 2 | 1.11 | |
| Adjusted low dose | 0.34 (0.19 to 0.58) | 13 | 0.34 (0.19 to 0.60) | 41 | 1.00 | |
| Fixed low dose | 0.76 (0.3 to 1.76) | 1 | 0.93 (0.36 to 2.66) | 1 | 1.22 | |
| Aspirin | 0.62 (0.43 to 0.86) | 0 | 0.66 (0.47 to 1.01) | 0 | 1.06 | |
| Fixed low dose warfarin+aspirin | 0.98 (0.6 to 1.67) | 0 | Removed | Removed | NA | |
| Ximelagatran | 0.34 (0.18 to 0.62) | 14 | 0.37 (0.21 to 0.83) | 13 | 1.09 | |
| Alternate day aspirin | 0.17 (0.01 to 1.15) | 66 | 0.45 (0.03 to 18.48) | 38 | 2.65 | |
| Indobufen | 0.46 (0.19 to 1.14) | 5 | 0.54 (0.23 to 1.57) | 6 | 1.17 | |
NA=not applicable.
*Average fold change reported in table 2 is averaged on log scale. The average of these fold changes is 1.33, slightly higher than 1.25.